These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18389878)

  • 1. [No reason to start treatment with statins in patients with moderate to severe heart failure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin in older patients with systolic heart failure.
    Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [To treat or not to treat with statins patients with chronic heart failure?].
    Hradec J
    Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?
    Rizzo M; Berneis K; Spinas GA; Rini GB; Kapur NK
    Int J Clin Pract; 2009 Mar; 63(3):478-85. PubMed ID: 19222633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid lowering by rosuvastatin: how do statins differ?].
    Laufs U
    Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    Wlodarczyk J; Sullivan D; Smith M
    Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
    McMurray JJ; Dunselman P; Wedel H; Cleland JG; Lindberg M; Hjalmarson A; Kjekshus J; Waagstein F; Apetrei E; Barrios V; Böhm M; Kamenský G; Komajda M; Mareev V; Wikstrand J;
    J Am Coll Cardiol; 2010 Oct; 56(15):1196-204. PubMed ID: 20883926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
    Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
    Ann Intern Med; 2010 Apr; 152(8):I34. PubMed ID: 20404365
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.